TY - JOUR
T1 - Evolutionary Approaches to Combat Antibiotic Resistance: Opportunities and Challenges for Precision Medicine
AU - Merker, Matthias
AU - Tueffers, Leif
AU - Vallier, Marie
AU - Groth, Espen E.
AU - Sonnenkalb, Lindsay
AU - Unterweger, Daniel
AU - Baines, John F.
AU - Niemann, Stefan
AU - Schulenburg, Hinrich
N1 - Funding Information:
Funding. This work was supported by the Cluster of Excellence in Precision Medicine in chronic Inflammation (EXC 2167-390884018), the German Center for Infection Research (DZIF) and the Leibniz Science Campus Evolutionary Medicine of the Lung (EvoLUNG).
Publisher Copyright:
© Copyright © 2020 Merker, Tueffers, Vallier, Groth, Sonnenkalb, Unterweger, Baines, Niemann and Schulenburg.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/27
Y1 - 2020/8/27
N2 - The rise of antimicrobial resistance (AMR) in bacterial pathogens is acknowledged by the WHO as a major global health crisis. It is estimated that in 2050 annually up to 10 million people will die from infections with drug resistant pathogens if no efficient countermeasures are implemented. Evolution of pathogens lies at the core of this crisis, which enables rapid adaptation to the selective pressures imposed by antimicrobial usage in both medical treatment and agriculture, consequently promoting the spread of resistance genes or alleles in bacterial populations. Approaches developed in the field of Evolutionary Medicine attempt to exploit evolutionary insight into these adaptive processes, with the aim to improve diagnostics and the sustainability of antimicrobial therapy. Here, we review the concept of evolutionary trade-offs in the development of AMR as well as new therapeutic approaches and their impact on host-microbiome-pathogen interactions. We further discuss the possible translation of evolution-informed treatments into clinical practice, considering both the rapid cure of the individual patients and the prevention of AMR.
AB - The rise of antimicrobial resistance (AMR) in bacterial pathogens is acknowledged by the WHO as a major global health crisis. It is estimated that in 2050 annually up to 10 million people will die from infections with drug resistant pathogens if no efficient countermeasures are implemented. Evolution of pathogens lies at the core of this crisis, which enables rapid adaptation to the selective pressures imposed by antimicrobial usage in both medical treatment and agriculture, consequently promoting the spread of resistance genes or alleles in bacterial populations. Approaches developed in the field of Evolutionary Medicine attempt to exploit evolutionary insight into these adaptive processes, with the aim to improve diagnostics and the sustainability of antimicrobial therapy. Here, we review the concept of evolutionary trade-offs in the development of AMR as well as new therapeutic approaches and their impact on host-microbiome-pathogen interactions. We further discuss the possible translation of evolution-informed treatments into clinical practice, considering both the rapid cure of the individual patients and the prevention of AMR.
UR - https://www.scopus.com/pages/publications/85091378565
U2 - 10.3389/fimmu.2020.01938
DO - 10.3389/fimmu.2020.01938
M3 - Scientific review articles
C2 - 32983122
AN - SCOPUS:85091378565
SN - 1664-3224
VL - 11
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1938
ER -
